Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBNX Beta Bionics	$16.73 +10.8%	$15.52	$8.89 ▼ $24.50	$727.25M	N/A	519,797 shs	449,885 shs
CVRX CVRx	$7.24 -6.3%	$6.95	$4.30 ▼ $18.55	$189.24M	1.27	325,320 shs	300,080 shs
EMBC Embecta	$13.86 -0.6%	$10.41	$9.20 ▼ $21.48	$810.66M	1.08	606,781 shs	416,264 shs
SIBN SiBone	$15.33 -2.4%	$17.48	$11.70 ▼ $20.05	$661.21M	0.91	432,398 shs	230,018 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBNX Beta Bionics	+6.19%	-0.66%	+17.69%	+9.66%	+1,509,999,900.00%
CVRX CVRx	+2.80%	+9.15%	+5.03%	+24.72%	-9.71%
EMBC Embecta	+4.65%	+41.24%	+34.43%	+19.55%	-5.94%
SIBN SiBone	+3.29%	-4.33%	-9.35%	-16.84%	+12.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBNX Beta Bionics	2.8154 of 5 stars	4.4	0.0	0.0	0.0	3.3	0.8	0.0
CVRX CVRx	2.7994 of 5 stars	3.4	1.0	0.0	0.0	2.4	4.2	0.6
EMBC Embecta	4.7685 of 5 stars	3.2	3.0	3.3	0.0	3.1	3.3	3.8
SIBN SiBone	4.163 of 5 stars	3.5	3.0	0.0	3.3	2.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBNX Beta Bionics	2.75	Moderate Buy	$22.56	51.58% Upside
CVRX CVRx	2.86	Moderate Buy	$14.00	89.70% Upside
EMBC Embecta	2.33	Hold	$19.00	40.91% Upside
SIBN SiBone	3.00	Buy	$23.67	55.13% Upside

Current Analyst Ratings Breakdown

Latest CVRX, SIBN, BBNX, and EMBC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	SIBN SiBone	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$25.00
8/5/2025	CVRX CVRx	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$11.00
8/5/2025	SIBN SiBone	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$25.00
7/30/2025	BBNX Beta Bionics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$18.00 ➝ $21.00
7/30/2025	BBNX Beta Bionics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral ➝ Neutral	$15.00 ➝ $17.00
7/16/2025	EMBC Embecta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$13.00 ➝ $12.00
7/7/2025	CVRX CVRx	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/16/2025	BBNX Beta Bionics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$26.00
6/12/2025	BBNX Beta Bionics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$30.00
5/30/2025	BBNX Beta Bionics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$16.00
5/30/2025	BBNX Beta Bionics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$20.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBNX Beta Bionics	$78.02M	8.29	N/A	N/A	$6.94 per share	2.14
CVRX CVRx	$54.65M	3.53	N/A	N/A	$2.22 per share	3.32
EMBC Embecta	$1.10B	0.72	$3.38 per share	3.99	($11.45) per share	-1.18
SIBN SiBone	$167.18M	3.94	N/A	N/A	$3.95 per share	3.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBNX Beta Bionics	-$54.76M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CVRX CVRx	-$59.97M	-$2.10	N/A	N/A	N/A	-95.61%	-79.31%	-40.96%	N/A
EMBC Embecta	$78.30M	$1.43	9.43	4.39	0.74	7.58%	-23.40%	14.46%	N/A
SIBN SiBone	-$30.91M	-$0.56	N/A	N/A	N/A	-12.83%	-14.20%	-10.38%	N/A

Latest CVRX, SIBN, BBNX, and EMBC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	Q3 2025	EMBC Embecta	$0.7720	$1.12	+$0.3480	$0.78	$278.15 million	$295.50 million
8/4/2025	Q2 2025	CVRX CVRx	-$0.52	-$0.57	-$0.05	-$0.57	$13.22 million	$13.59 million
8/4/2025	Q2 2025	SIBN SiBone	-$0.19	-$0.14	+$0.05	-$0.14	$48.12 million	$48.63 million
7/29/2025	Q2 2025	BBNX Beta Bionics	-$0.51	-$0.39	+$0.12	-$0.39	$19.73 million	$23.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBNX Beta Bionics	N/A	N/A	N/A	N/A	N/A
CVRX CVRx	N/A	N/A	N/A	N/A	N/A
EMBC Embecta	$0.60	4.45%	N/A	41.96%	N/A
SIBN SiBone	N/A	N/A	N/A	N/A	N/A

Latest CVRX, SIBN, BBNX, and EMBC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/6/2025	EMBC Embecta	quarterly	$0.15	5.79%	8/29/2025	8/29/2025	9/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBNX Beta Bionics	N/A	14.68	13.79
CVRX CVRx	0.85	11.99	10.78
EMBC Embecta	N/A	2.47	1.78
SIBN SiBone	0.21	8.38	7.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBNX Beta Bionics	N/A
CVRX CVRx	75.27%
EMBC Embecta	93.83%
SIBN SiBone	98.11%

Insider Ownership

Company	Insider Ownership
BBNX Beta Bionics	N/A
CVRX CVRx	13.90%
EMBC Embecta	0.42%
SIBN SiBone	4.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBNX Beta Bionics	294	43.47 million	N/A	N/A
CVRX CVRx	160	26.15 million	22.52 million	Optionable
EMBC Embecta	2,100	58.49 million	58.24 million	Optionable
SIBN SiBone	350	43.14 million	41.42 million	Optionable

CVRX, SIBN, BBNX, and EMBC Headlines

Recent News About These Companies

SiBone (NASDAQ:SIBN) Director John Gordon Freund Sells 12,132 Shares

August 12 at 8:06 PM | marketbeat.com

Insider Selling: SiBone (NASDAQ:SIBN) Director Sells 12,132 Shares of Stock

August 12 at 4:53 AM | insidertrades.com

SiBone (NASDAQ:SIBN) Stock Rating Lowered by Wall Street Zen

August 10, 2025 | marketbeat.com

FY2025 EPS Estimates for SiBone Boosted by Cantor Fitzgerald

August 9, 2025 | marketbeat.com

FY2025 EPS Estimates for SiBone Raised by Cantor Fitzgerald

August 9, 2025 | americanbankingnews.com

SiBone (NASDAQ:SIBN) Shares Down 13.1% - Here's What Happened

August 6, 2025 | marketbeat.com

SiBone (NASDAQ:SIBN) Earns "Overweight" Rating from Cantor Fitzgerald

August 6, 2025 | marketbeat.com

SiBone (NASDAQ:SIBN) Issues Quarterly Earnings Results

August 5, 2025 | marketbeat.com

SI-Bone Reports Strong Q2 2025 Financial Results

August 5, 2025 | msn.com

SI-BONE, Inc. (SIBN) Q2 2025 Earnings Call Transcript

August 5, 2025 | seekingalpha.com

SI-BONE, Inc. 2025 Q2 - Results - Earnings Call Presentation

August 4, 2025 | seekingalpha.com

Si-Bone (SIBN) Reports Q2 Loss, Beats Revenue Estimates

August 4, 2025 | zacks.com

SI-BONE, Inc. Reports Financial Results for the Second Quarter 2025 and Raises 2025 Guidance

August 4, 2025 | globenewswire.com

Universal Beteiligungs und Servicegesellschaft mbH Acquires New Holdings in SiBone (NASDAQ:SIBN)

August 3, 2025 | marketbeat.com

SI-BONE To Present at Canaccord Genuity 45th Annual Growth Conference on August 12, 2025

July 29, 2025 | globenewswire.com

SiBone (SIBN) Projected to Post Quarterly Earnings on Monday

July 28, 2025 | marketbeat.com

Victory Capital Management Inc. Raises Stock Holdings in SiBone (NASDAQ:SIBN)

July 25, 2025 | marketbeat.com

Legato Capital Management LLC Acquires 36,649 Shares of SiBone (NASDAQ:SIBN)

July 24, 2025 | marketbeat.com

SI-BONE To Report Second Quarter 2025 Financial Results on August 4, 2025

July 14, 2025 | globenewswire.com

Insider Selling: SiBone (NASDAQ:SIBN) CEO Sells 757 Shares of Stock

July 8, 2025 | insidertrades.com

All You Need to Know About Si-Bone (SIBN) Rating Upgrade to Buy

July 7, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVRX, SIBN, BBNX, and EMBC Company Descriptions

Beta Bionics NASDAQ:BBNX

$16.73 +1.63 (+10.79%)

As of 03:51 PM Eastern

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

CVRx NASDAQ:CVRX

$7.24 -0.48 (-6.27%)

Closing price 03:59 PM Eastern

Extended Trading

$7.24 +0.01 (+0.12%)

As of 04:10 PM Eastern

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Embecta NASDAQ:EMBC

$13.86 -0.08 (-0.57%)

Closing price 03:59 PM Eastern

Extended Trading

$13.94 +0.08 (+0.57%)

As of 04:10 PM Eastern

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

SiBone NASDAQ:SIBN

$15.33 -0.37 (-2.38%)

Closing price 03:59 PM Eastern

Extended Trading

$15.29 -0.04 (-0.24%)

As of 04:10 PM Eastern

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time